Department of Urology, University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City, OK, USA.
Investig Clin Urol. 2020 Feb;61(Suppl 1):S3-S7. doi: 10.4111/icu.2020.61.S1.S3. Epub 2020 Jan 16.
Metastatic prostate cancer is a heterogeneous disease entity. Men without prior androgen deprivation therapy exposure are termed metastatic castration sensitive prostate cancer (mCSPC). The goal of this article is to update the reader on the rapidly changing landscape of treatment for men with mCSPC. Along with the options available to the clinician for treatment of men with mCSPC, the care of these patients has evolved into a multi-disciplinary field with expanding roles for medical, urologic, and radiation oncologists.
转移性前列腺癌是一种异质性疾病实体。未经雄激素剥夺治疗（androgen deprivation therapy）暴露的男性被称为转移性去势敏感前列腺癌（metastatic castration sensitive prostate cancer，mCSPC）。本文的目的是使读者了解 mCSPC 男性治疗领域的快速变化。随着临床医生为 mCSPC 男性提供的治疗选择的增加，这些患者的护理已发展成为一个多学科领域，医学、泌尿科和放射肿瘤学家的角色不断扩大。
